Atara Biotherapeutics, Inc. (ATRA)
Valuation Overview•Is Atara Biotherapeutics, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Fragile underlying quality score of 39/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street sentiment is generally neutral. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
ATRA struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is driving exceptional top-line expansion (23.9% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-27.3%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $516K | -6.3% | +23.9% | — | — | |
| EBITDA | -$3.3M | — | — | — | — | |
| Net Income | -$4.1M | +138.3% | — | — | — | |
| EPS (Diluted) | $-0.29 | +122.5% | — | — | — | |
| Free Cash Flow | -$3.1M | +26.1% | +43.0% | +22.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 96.1% | 54.2% | -204.8% | -204.8% |
| Operating Margin | -27.3% | -1084.8% | -1073.9% | -1073.9% |
| Net Margin | -40.9% | -1086.7% | -1058.3% | -1058.3% |
| FCF Margin | -111.8% | -787.0% | -785.8% | -785.8% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.33 | $-0.29 | +12.0% | ||
| Q1'26 | $-0.09 | $-0.25 | -177.8% | ||
| Q4'25 | $-0.83 | $-0.32 | +61.4% | ||
| Q3'25 | $-0.32 | $0.19 | +159.4% | ||
| Q2'25 | $-3.07 | $3.50 | +214.0% | ||
| Q1'25 | $-3.82 | $-1.19 | +68.8% | ||
| Q4'24 | $-3.77 | $-2.93 | +22.3% | ||
| Q3'24 | $-1.25 | $-3.10 | -148.0% |
Total return is +25.6% (1Y), outperforming the benchmark by +0.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -43.3% | -52.6% | — |
| 1Y | +25.6% | +0.6% | — |
| 3YCAGR | -40.5% | -60.8% | — |
| 5YCAGR | -51.5% | -64.6% | — |
| 10YCAGR | -32.7% | -46.2% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Atara Biotherapeutics, Inc. (ATRA) valuation, health, and returns.
Based on peer relative multiples, Atara Biotherapeutics, Inc. appears Cheap versus peers compared to industry peers.
Atara Biotherapeutics, Inc. has multiple valuation anchors: Peer Relative Fair Value: $62.64. A convergence of these signals offers higher conviction.
Atara Biotherapeutics, Inc. displays weak financial health with a composite quality score of 39/100, supported by a Altman Z-Score of -100.0 (distress zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of 462.6%.
Atara Biotherapeutics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Atara Biotherapeutics, Inc.'s current growth trajectory is Decelerating. The company achieved -6.3% 1Y revenue growth and +122.5% 1Y EPS growth, compared to its 3Y revenue CAGR of +23.9%.
Wall Street consensus is Hold based on 0 analysts, beating EPS expectations in 67% of recent quarters with a 1-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Atara Biotherapeutics, Inc. include: -76.9% 1-year max drawdown, high beta (1.39x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.39x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.